Terpene Innovation
Pulmonara Labs is developing innovative IPF therapies aimed at improving efficacy, safety, and convenience while addressing unmet patient needs. Supported by a dedicated team of scientists, researchers, experts, and advisors, we strive to expand treatment options and advance the standard of care through rigorous research and continuous improvement, supporting better outcomes for patients and their families.
PUL-001
PUL-001 is an inhaled sterile drug product to serve as a treatment for idiopathic pulmonary fibrosis (IPF) by inhibiting a key modulator/essential transcription factor of pulmonary fibrosis pathogenesis, Nuclear Factor Kappa of B cells (NF-κB).
NF-κB Pathway - Canonical & Non-Canonical
PUL-001Â Selective Inhibition of
NF-κB
Platform & IP Strategy: PUL-002 & Beyond
Discovery Platform
Informed Lead Selection
IP & Portfolio Value
Naturally occurring terpenes provide chemical starting points for a broader discovery strategy. Pulmonara leverages lead program findings to design optimized derivatives targeting potency, selectivity, and stability for diverse inhalation-based treatments.
Pulmonara starts with compounds for which published pharmacology and exposure information can inform candidate selection, identify safety questions and focus on experimental work that can only expand upon current research rather than duplicate.
Pulmonara has secured a provisional patent for naturally occurring terpene solutions, building a portfolio ready for clinical evolution. This creates vast potential for licensing, asset auctions, and new molecular designs beyond original fibrotic lung disease indications.
Invest in Innovation
Pulmonara offers an opportunity to turn existing knowledge into proprietary pulmonary medicines. The lead program focuses that opportunity on IPF, while subsequent medicinal chemistry can create additional drug products with their own clinical profiles and commercial protection.
For investors and pharmaceutical partners, Pulmonara offers a focused lead-product opportunity alongside the potential to generate successive proprietary therapies. Its competitive position will strengthen as it establishes differentiated clinical performance, reproducible manufacturing, practical patient access, and defensible intellectual property.
